Viking Therapeutics Catapults 73% As Weight-Loss Drug Beats Out Lilly ' s Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock nearly doubled, while Lilly shares slumped. The post Viking Therapeutics Catapults 73% As Weight-Loss Drug Beats Out Lilly's Zepbound appeared first on Investor's Business Daily.#lilly #zepbound

Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news